<DOC>
	<DOCNO>NCT02995850</DOCNO>
	<brief_summary>This open-label , non-randomized , single-center , phase Ib/II study , evaluate efficacy feasibility cytoreductive surgery ( CRS ) , extensive peritoneal lavage , hyperthermic intraperitoneal chemotherapy ( HIPEC ) post-operative intraperitoneal chemotherapy combination gastric cancer peritoneal metastasis</brief_summary>
	<brief_title>A Phase Ib/II Study Efficacy Feasibility Cytoreductive Surgery , Extensive Peritoneal Lavage , Hyperthermicintraperitoneal Chemotherapy Post-operative Intraperitoneal Chemotherapy Combination Gastric Cancer With Peritoneal Metastasis</brief_title>
	<detailed_description>Peritoneal metastasis gastric cancer consider indicate terminal disease due poor prognosis systemic chemotherapy unlikely accumulate peritoneal nodule cytotoxic concentration . Cytoreductive surgery ( CRS ) along hyperthermic intraperitoneal chemotherapy ( HIPEC ) suggest improve survival select patient limited peritoneal spread , result median overall survival ( OS ) 8 14 month . It remain unclear , however , regimen best benefit CRS HIPEC . Herein , conduct prospective phase Ib/II trial CRC HIPEC intraperitoneal paclitaxel cisplatin , oral S-1 gastric cancer peritoneal metastasis .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>1 . Patient age 19 year old age 75 year younger . 2 . Histologically proven gastric esophagogastric junction adenocarcinoma peritoneal metastasis diagnostic laparoscopy . 3 . Primary tumor measure resectable preoperative image . 4 . Performance status base ECOG : 0~1 5 . No prior treatment ( chemotherapy , radiotherapy , etc . ) 6 . Adequate hepatic , renal , hematologic function ANC≥1,500/uL , hemoglobin≥9.0g/dL platelet≥100,000/uL total Bilirubin : ≤ 1.5 × upper normal limit Creatinine &lt; 1.5mg/dL AST/ALT , ALP ≤ 2.5 x upper normal limit 7 . Patients understand study sign consent form . 1 . Patient distant metastasis paraaortic lymph node metastasis retroperitoneal metastasis except peritoneal metastasis . ( But patient ovarian metastasis resectable status enrol . ) 2 . Primary tumor resect direct invasion important organ . ( But , invade organ resect together , spleen , gallbladder , distal pancreas , liver , patient enrol ) 3 . HER2 positive patient 4 . Patient active viral infection ( example , HIV , HBV , HCV , except stable status HBV infection ) 5 . Pregnant patient , patient breastfeeding , plan pregnancy . 6 . Patients exclusion criterion TS1 , cisplatin , paclitaxel Patients history severe hypersensitivity drug Patients severe bone marrow depression patient severe hepatic , renal disorder patient hereditary problem galactose intolerance , lapp lactase deficiency , glucosegalactose malabsorption 7 . Patients important medical problem infection Cerebrovascular accident ( CVA ) within 1 year Heart attack within 6 month , uncontrolled hypertension , unstable angina , uncontrolled congestive heart failure ( CHF ) , severe arrhythmia Major operation injury within 28 day Severe recover wound , ulcer , fracture Uncontrolled bleeding disease Recent active gastric infection 8 . Patient another primary cancer within last 5 year 9 . Patient medication interact drug use study ( fluoropyrimidinegroup antineoplastic agent , flucytosine , phenytoin , etc ) 10 . Patients systemic chemotherapy radiotherapy 11 . Patients psychiatric neurologic disorder understand sign consent form .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>